Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Mar 27, 2024; 16(3): 882-892
Published online Mar 27, 2024. doi: 10.4240/wjgs.v16.i3.882
Etanercept-synthesizing adipose-derived stem cell secretome: A promising therapeutic option for inflammatory bowel disease
Say-June Kim, Ok-Hee Kim, Ha-Eun Hong, Ji Hyeon Ju, Do Sang Lee
Say-June Kim, Do Sang Lee, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul 06591, South Korea
Say-June Kim, Ok-Hee Kim, Ha-Eun Hong, Catholic Central Laboratory of Surgery, Institute of Biomedical Industry, College of Medicine, the Catholic University of Korea, Seoul 06591, South Korea
Ji Hyeon Ju, Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea
Author contributions: Lee DS was responsible for planning the study, data interpretation, and manuscript preparation; Kim SJ wrote the article, conducted experiments, and participated in data analysis and interpretation; Kim OH, Ju JH, and Hong HE participated in the in vitro and in vivo experiments and analysis and interpretation of data; All authors read and approved the manuscript.
Supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT), No. NRF-2021R1F1A1064566.
Institutional review board statement: Human adipose-derived stem cells were acquired from Hurim BioCell Co., Seoul, Republic of Korea, Institutional Review Board No. 700069-201407-BR-002-01.
Institutional animal care and use committee statement: Five-week-old male BALB/c mice, sourced from Orient Bio (Seongnam, Republic of Korea), were used in this animal experiment, conducted in compliance with the Institute for Laboratory Animal Research guidelines at the Catholic University of Korea, Institutional Review Board No. CUMC- 2022-0020-01.
Conflict-of-interest statement: Dr. Lee reports grants from National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT), during the conduct of the study; In addition, Dr. Lee has a patent 10-2023-0193643 pending to Catholic University Industry-Academic Cooperation Foundation.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Do Sang Lee, MD, PhD, Doctor, Professor, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, South Korea. dosangs@catholic.ac.kr
Received: November 9, 2023
Peer-review started: November 9, 2023
First decision: December 8, 2023
Revised: January 3, 2024
Accepted: February 3, 2024
Article in press: February 3, 2024
Published online: March 27, 2024
ARTICLE HIGHLIGHTS
Research background

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, significantly influenced by tumor necrosis factor (TNF)-α. Etanercept, a TNF decoy receptor, along with the anti-inflammatory secretome from adipose-derived stem cells (ASCs), offers a novel approach for IBD therapy.

Research motivation

This study aims to address the limitations of current IBD treatments by exploring the combined anti-inflammatory effects of ASC-derived secretome and etanercept, potentially offering a more comprehensive and effective treatment strategy for IBD.

Research objectives

To investigate the anti-inflammatory efficacy of the secretome from etanercept-synthesizing ASCs in colon cells and a dextran sulfate sodium (DSS)-induced IBD mouse model, assessing its potential as a novel therapeutic agent for IBD treatment.

Research methods

ASCs were transfected with etanercept-encoding plasmids, producing a specialized secretome. This Etanercept-secretome (Et-Sec) was evaluated for anti-inflammatory effects both in vitro in colon cells and in vivo in a DSS-induced IBD mouse model.

Research results

Et-Sec group, treated with the secretome from etanercept-synthesizing ASCs, showed a substantial reduction in the expression of inflammatory mediators, including interleukin-6, Monocyte Chemoattractant Protein-1, and TNF-α, relative to the control secretome group. Furthermore, the Et-Sec group displayed a significant therapeutic benefit by better preserving the structure of intestinal tissues, highlighting its potential in treating inflammatory bowel disease.

Research conclusions

The study concludes that the Et-Sec from ASCs significantly reduces inflammatory markers and mitigates tissue damage in IBD, demonstrating its potential as an effective therapeutic agent for IBD treatment.

Research perspectives

Future research should focus on further validating the efficacy of Et-Sec in diverse IBD models and exploring its potential as a comprehensive treatment strategy for various forms of IBD.